Quantcast

Latest torsades de pointes Stories

2011-04-11 07:30:00

ALISO VIEJO, Calif., April 11, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of William (Bill) Sibold to the position of senior vice president and chief commercial officer. In this newly created role, Mr. Sibold will be responsible for leading all of the company's commercial activities. "Bill has an outstanding track record of success in biopharmaceutical sales and marketing," said Keith A. Katkin, president and CEO of Avanir. "I am...

2011-04-07 15:05:00

ALISO VIEJO, Calif., April 7, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from a number of clinical research activities will be highlighted at the 63rd Annual Meeting of the American Academy of Neurology (AAN), taking place in Honolulu, HI, at the Hawaii Convention Center from April 9 through 16, 2011. Following are details about the data presentations: Title: Burden of Pseudobulbar Affect on Social Function and Quality of...

2011-02-09 13:32:36

Long QT syndrome approximately affects one in every 2,500 people ­-mainly young people. It can cause torsade de pointes episodes, which can trigger sudden death. This study was conducted by researchers of the Hospital Virgen de las Nieves of the University of Granada. The genetic analyses were performed by the laboratory Lorgen in the Health Science Technology Park of Granada Researchers from the Hospital Virgen de las Nieves of the University of Granada have identified the...

2011-02-03 07:30:00

ALISO VIEJO, Calif., Feb. 3, 2011 /PRNewswire/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today reported unaudited financial results for the three months ended December 31, 2010. For the first quarter of fiscal 2011, AVANIR reported a net loss of $12.1 million, or $0.11 loss per share, compared with a net loss of $4.8 million, or $0.06 loss per share, for the same period in fiscal 2010. Net revenues consisting primarily of royalty revenue were $1.8 million and $1.5 million for the...

2010-11-18 07:30:00

KING OF PRUSSIA, Pa., Nov. 18, 2010 /PRNewswire/ -- Prism Pharmaceuticals, Inc. announced today that the U.S. Food & Drug Administration (FDA) has approved the supplemental new drug application for NEXTERONE® (amiodarone HCl) Premixed Injection, the first and only premixed intravenous (IV) bag formulation of the antiarrhythmic agent amiodarone IV. NEXTERONE Premixed Injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular...

2010-11-01 06:00:00

ALISO VIEJO, Calif., Nov. 1, 2010 /PRNewswire-FirstCall/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced a management conference call to discuss the approval of NUEDEXTA(TM) (dextromethorphan hydrobromide and quinidine sulfate) by the U.S. Food and Drug Administration (FDA). The call is scheduled for today, Monday November 1, 2010 at 5:15 a.m. Pacific time / 8:15 a.m. Eastern time. The live call can be accessed by dialing (877) 558-3407 for domestic callers and (706)...

2010-10-21 10:50:00

Drug associated with a life-threatening heart abnormality when used with another antiviral medicine SILVER SPRING, Md., Oct. 21 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that new safety information has been added to the label for the HIV antiviral drug Invirase (saquinavir), describing potentially life-threatening side effects on the heart when used with Norvir (ritonavir), another HIV antiviral medication. (Logo:...

2010-02-23 10:21:00

Review of data indicating life-threatening heart abnormality underway SILVER SPRING, Md., Feb. 23 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced preliminary data suggesting that Invirase (saquinavir) in combination with Norvir (ritonavir) may have potentially important adverse effects on the heart. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) When used together, the drugs may cause prolongation of the QT and PR intervals on an...

2010-02-08 14:45:00

DALLAS, Feb. 8 /PRNewswire-USNewswire/ -- Hospital care providers need to be more aware that cardiac arrest from a medication-induced heart rhythm problem is a rare but potentially catastrophic event in patients, according to a joint scientific statement from the American Heart Association and American College of Cardiology. The statement, published online in Circulation: Journal of the American Heart Association and Journal of the American College of Cardiology, is endorsed by the...

2008-08-13 18:00:12

By Erdogan, Okan Aksoy, Alper; Turgut, Nilda; Durusoy, Elcim; Samsa, Murat; Altun, Armagan Abstract Andersen-Tawil syndrome (ATS) is a rare, heterogeneous, autosomal dominant, or sporadic disorder characterized by the clinical triad of periodic paralysis, dysmorphic features, and ventricular arrhythmias such as bidirectional ventricular tachycardia (BVT). We present a case of an elderly patient with ATS whose symptomatic ventricular arrhythmias including BVT were effectively suppressed by...


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.